Učitavanje...
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
OBJECTIVE: To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. METHODS: Patients aged 4–10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice daily. The double-blind trial...
Spremljeno u:
| Izdano u: | Neurology |
|---|---|
| Glavni autori: | , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Lippincott Williams & Wilkins
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5890607/ https://ncbi.nlm.nih.gov/pubmed/29540584 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000005254 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|